S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
All the trading advice you’ve ever received boils down to this (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
All the trading advice you’ve ever received boils down to this (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
All the trading advice you’ve ever received boils down to this (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
All the trading advice you’ve ever received boils down to this (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
All the trading advice you’ve ever received boils down to this (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

Summit Therapeutics Stock Price, News & Analysis (NASDAQ:SMMT)

$2.19
-0.03 (-1.35%)
(As of 12/8/2023 ET)
Compare
Today's Range
$2.17
$2.25
50-Day Range
$1.67
$2.46
52-Week Range
$1.25
$5.78
Volume
701,103 shs
Average Volume
970,956 shs
Market Capitalization
$1.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SMMT stock logo

About Summit Therapeutics Stock (NASDAQ:SMMT)

Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company's product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. for research and develop Ivonescimab (AK112) and SMT112, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.

SMMT Stock Price History

SMMT Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Summit Therapeutics: Not For Retail Investors
Q2 2023 Summit Therapeutics Inc Earnings Call
11 Stocks with Heavy Insider Buying in 2023
Q1 2023 Summit Therapeutics Inc Earnings Call
See More Headlines
Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SMMT
Employees
76
Year Founded
N/A

Profitability

Net Income
$-78,780,000.00
Pretax Margin
-271,685.00%

Debt

Sales & Book Value

Annual Sales
$700,000.00
Book Value
$0.60 per share

Miscellaneous

Free Float
114,237,000
Market Cap
$1.53 billion
Optionable
Optionable
Beta
-0.97
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Robert W. DugganMr. Robert W. Duggan (Age 79)
    Co-CEO & Executive Chairman
  • Dr. Mahkam Zanganeh D.D.S. (Age 53)
    M.B.A., Co-CEO, President & Director
    Comp: $934.85k
  • Mr. Ankur Dhingra (Age 47)
    Chief Financial Officer
    Comp: $668.39k
  • Mr. Manmeet Singh Soni (Age 45)
    COO & Director
  • Dr. Urte Gayko Ph.D. (Age 52)
    Chief Regulatory, Quality & Pharmacovigilance Officer?
  • Prof. Dame Kay Davies DBE (Age 72)
    FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
  • Ms. Shelley D. Spray (Age 58)
    Head of Corporate Education, Communications & Creative?
  • Ms. Abby Guzman Murphy
    Head of Human Resources
  • Ms. Divya Chari (Age 55)
    Head of Global Clinical Operations
  • Mr. Dave Gancarz
    Chief Business & Strategy Officer?














SMMT Stock Analysis - Frequently Asked Questions

How have SMMT shares performed in 2023?

Summit Therapeutics' stock was trading at $4.25 on January 1st, 2023. Since then, SMMT stock has decreased by 48.5% and is now trading at $2.19.
View the best growth stocks for 2023 here
.

When is Summit Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our SMMT earnings forecast
.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) announced its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company earned $0.27 million during the quarter.

What ETFs hold Summit Therapeutics' stock?

ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Summit Therapeutics own?
When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.15%), Charles Schwab Investment Management Inc. (0.13%), Shell Asset Management Co. (0.05%), California State Teachers Retirement System (0.02%), Barclays PLC (0.02%) and Rhumbline Advisers (0.02%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan.
View institutional ownership trends
.

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SMMT) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -